Clinical trial
Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer
NCT00057915 · Duke University, Other · Completed
Key facts
| NCT number | NCT00057915 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer |
| Official title | A Phase I Study of Active Immunotherapy With CAP-1 (6D) and CMVpp65 Peptide-Pulsed, Autologous Dendritic Cells Produced in the Aastromreplicell Cell Production System in Patients With Stage IV CEA Expressing Malignancies |
| Lead sponsor | Duke University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | CEA peptide 1-6D |
| Enrollment | 4 |
| Start date | Sep 1, 2003 |
| Primary completion | Aug 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Apr 9, 2003 |
| Last update posted | Sep 8, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: